Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04346381 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor | completed | Phase 2 | 233 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06041035 | A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 115 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2023 |
| NCT05284214 | Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors(SALIENT) | withdrawn | Phase 2 | 0 | Partner Therapeutics, Inc.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | completed | Phase 1 / Phase 2 | 39 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06008366 | A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 281 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06008379 | A Study of 7MW3711 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 164 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 12 | NBE-Therapeutics AGINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT06026501 | A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor | not yet recruiting | Phase 1 / Phase 2 | 120 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Sep 7, 2023 | clinicaltrials |
| NCT06022289 | Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors | unknown | Phase 2 | 20 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT03834948 | AO-176 in Multiple Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 57 | Arch OncologyINDUSTRY | 1 | Aug 22, 2023 | clinicaltrials |
| NCT05986981 | MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05840835 | Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors(IMMINENT-01) | unknown | Phase 1 / Phase 2 | 60 | Immix Biopharma, Inc.INDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT03926143 | A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies | terminated | Phase 2 | 9 | BayerINDUSTRY | 4 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02506517 | A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene | completed | Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT04250948 | Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer | unknown | Phase 2 | 108 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05396339 | A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 120 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05173805 | Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation | unknown | Phase 1 / Phase 2 | 150 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05947487 | CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05944185 | Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT03718091 | M6620 (VX-970) in Selected Solid Tumors | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05934539 | ALG.APV-527 First-in-human Study | unknown | Phase 1 / Phase 2 | 56 | Aptevo TherapeuticsINDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05116891 | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Cantargia ABINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
| NCT03989115 | Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC | completed | Phase 1 / Phase 2 | 113 | Revolution Medicines, Inc.INDUSTRY | 2 | Jun 26, 2023 | clinicaltrials |
| NCT05915481 | Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors(SCARCE) | unknown | Phase 1 / Phase 2 | 60 | Peking University Third HospitalOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT02797977 | A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects | completed | Phase 1 / Phase 2 | 153 | Sierra Oncology LLC - a GSK companyINDUSTRY | 2 | Jun 22, 2023 | clinicaltrials |
| NCT05909436 | Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors | recruiting | Phase 1 / Phase 2 | 107 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05268666 | A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 126 | Jubilant Therapeutics Inc.INDUSTRY | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05904457 | A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer(BRISK) | unknown | Phase 2 | 32 | Asan Medical CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04122625 | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143(SMARTPLUS-106) | completed | Phase 1 / Phase 2 | 46 | Debiopharm International SAINDUSTRY | 3 | Jun 12, 2023 | clinicaltrials |
| NCT04471415 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | Dracen Pharmaceuticals, Inc.INDUSTRY | 5 | Jun 12, 2023 | clinicaltrials |
| NCT05898451 | Effect of Refnot on Immunity in Cancer Patients(R-2) | completed | Phase 2 | 55 | Refnot-Pharm LtdINDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05869240 | BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 388 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 6, 2023 | clinicaltrials |
| NCT01752920 | Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations | completed | Phase 1 / Phase 2 | 119 | Basilea PharmaceuticaINDUSTRY | 2 | Jun 5, 2023 | clinicaltrials |
| NCT05794477 | A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 132 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | terminated | Phase 1 / Phase 2 | 63 | 4D pharma plcINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05207787 | Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 306 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05862831 | Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 285 | Biotheus Inc.INDUSTRY | 1 | May 17, 2023 | clinicaltrials |
| NCT00886782 | A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 11 | Bristol-Myers SquibbINDUSTRY | 3 | Apr 28, 2023 | clinicaltrials |
| NCT05833984 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | unknown | Phase 1 / Phase 2 | 309 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04775680 | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 25 | Adagene (Suzhou) LimitedINDUSTRY | 1 | Apr 24, 2023 | clinicaltrials |
| NCT04696848 | The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 25 | Tae Won KimOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT02426892 | Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT03577704 | The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.(HLX07Ib/II) | completed | Phase 1 / Phase 2 | 56 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04571892 | A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 58 | Shanghai East HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 18, 2023source: clinicaltrials